Omnicell (NASDAQ:OMCL - Get Free Report) was upgraded by stock analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Thursday.
A number of other research analysts have also issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Wells Fargo & Company lowered their target price on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Bank of America cut their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Finally, Benchmark restated a "buy" rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Omnicell currently has a consensus rating of "Hold" and an average price target of $52.33.
Check Out Our Latest Analysis on Omnicell
Omnicell Stock Performance
Omnicell stock traded down $1.05 during midday trading on Thursday, reaching $35.94. 476,876 shares of the stock traded hands, compared to its average volume of 491,461. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of 133.12, a PEG ratio of 7.53 and a beta of 0.85. The firm has a fifty day moving average price of $41.74 and a two-hundred day moving average price of $43.64. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities research analysts forecast that Omnicell will post 1.09 earnings per share for the current year.
Insider Transactions at Omnicell
In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now directly owns 58,427 shares of the company's stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 2.64% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Omnicell
A number of institutional investors and hedge funds have recently modified their holdings of OMCL. Victory Capital Management Inc. increased its holdings in shares of Omnicell by 11,982.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company's stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. bought a new position in Omnicell during the third quarter worth $32,721,000. Lazard Asset Management LLC increased its holdings in shares of Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after purchasing an additional 737,536 shares during the last quarter. Toronto Dominion Bank bought a new position in shares of Omnicell in the fourth quarter valued at about $30,637,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after buying an additional 394,820 shares during the last quarter. 97.70% of the stock is owned by institutional investors.
About Omnicell
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Further Reading
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
